Risk of Second Cancers According to Radiation Therapy Technique and Modality in Prostate Cancer Survivors

Abstract

Purpose Radiation therapy (RT) techniques for prostate cancer are evolving rapidly, but the impact of these changes on risk of second cancers, which are an uncommon but serious consequence of RT, are uncertain. We conducted a comprehensive assessment of risks of second cancer according to RT technique (>10 MV vs ≤10 MV and 3-dimensional [3D] vs 2D RT) and modality (external beam RT, brachytherapy, and combined modes) in a large cohort of prostate cancer patients. Methods and Materials The cohort was constructed using the Surveillance Epidemiology and End Results-Medicare database. We included cases of prostate cancer diagnosed in patients 66 to 84 years of age from 1992 to 2004 and followed through 2009. We used Poisson regression analysis to compare rates of second cancer across RT groups with adjustment for age, follow-up, chemotherapy, hormone therapy, and comorbidities. Analyses of second solid cancers were based on the number of 5-year survivors (n = 38,733), and analyses of leukemia were based on number of 2-year survivors (n = 52,515) to account for the minimum latency period for radiation-related cancer. Results During an average of 4.4 years' follow-up among 5-year prostate cancer survivors (2DRT = 5.5 years; 3DRT = 3.9 years; and brachytherapy = 2.7 years), 2933 second solid cancers were diagnosed. There were no significant differences in second solid cancer rates overall between 3DRT and 2DRT patients (relative risk [RR] = 1.00, 95% confidence interval [CI]: 0.91-1.09), but second rectal cancer rates were significantly lower after 3DRT (RR = 0.59, 95% CI: 0.40-0.88). Rates of second solid cancers for higher- and lower-energy RT were similar overall (RR = 0.97, 95% CI: 0.89-1.06), as were rates for site-specific cancers. There were significant reductions in colon cancer and leukemia rates in the first decade after brachytherapy compared to those after external beam RT. Conclusions Advanced treatment planning may have reduced rectal cancer risks in prostate cancer survivors by approximately 3 cases per 1000 after 15 years. Despite concerns about the neutron doses, we did not find evidence that higher energy therapy was associated with increased second cancer risks.

Risk of second primary cancer in patients treated with radiotherapy for rectal cancer

“…The effect of the fractional dose of RT on the risk of developing a second primary cancer is not clear. Most irradiated patients in this study were treated with 5‐Gy fractions.…”

Trends in the use of radiation therapy for stage IIA prostate cancer from 2004 to 2013: a retrospective analysis using the National Cancer Database

“…A recent SEER study showed that although there was no difference in the overall risk of developing secondary solid cancers for patients treated with the now antiquated two-dimensional technique compared to the newer three-dimensional technique, there were significantly fewer secondary rectal cancers using three-dimensional radiation therapy. 30 In addition, patients receiving EBRT alone had significantly higher rates of grade 2 or higher gastrointestinal toxicities, mainly rectal bleeding. 31 These concerns of toxicity, along with patient inconvenience associated with traveling to the clinic multiple times per week, are likely contributing to the decline of EBRT relative to surgery.…”

Quality of life after brachytherapy or bilateral nerve‐sparing robot‐assisted radical prostatectomy for prostate cancer: a prospective cohort

“…These include nerve‐sparing prostatectomy and brachytherapy, which are usually preferred for younger patients as they are carried out in one setting . In addition, compared with external beam radiotherapy, brachytherapy avoids the low‐dose ‘bath’ for surrounding tissue .…”